The head of the Oxford Vaccine Group said Friday that clinic trials on its vaccine for the coronavirus are"progressing very well."
Oxford University has an exclusive deal with the company Oxford Sciences Innovation to commercialise all its research - and a SA fund manager is the largest shareholder in OSI.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: